Dr James Wilmott awarded for outstanding cancer research
6 August 2016
Research Associate at Melanoma Institute Australia, Dr James Wilmott, was awarded the Wildfire Award at last night's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The 'Wildfire' Highly Cited Publication Award is given to a NSW researcher who has made a significant difference to cancer research, care or practice through authoring a highly cited publication that is expected to significantly influence cancer control or further research.
His publication ‘Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma external’ is being used by pathology departments around the world to triage patients into lifesaving personalised medicines.
Some patients only have days to live without intervention and cannot wait for routine molecular testing results.
The assay described in the publication allows patients who could die waiting to be tested and treated with lifesaving drugs.
Dr Wilmott has authored more than 50 manuscripts which have been cited over 1400 times. His research interests are biomarker studies of patients treated with targeted therapies and he is currently working as the Project Manager for the Australian Melanoma Genome Project.
As part of the prestigious award, Dr Wilmott will be granted $20,000 to future research endeavours.
Previous winners of the Wildfire Award from MIA include Prof Georgina Long (in 2014) and A/Prof Pascale Guitera (in 2013).
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Independent researchers at The University of Sydney are seeking patient feedback.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!